Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.73, sa.3, ss.631-637, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 73 Sayı: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s00280-014-2396-x
  • Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.631-637
  • Anahtar Kelimeler: Serum, EGFR, Ovarian cancer, Prognostic factor
  • İstanbul Üniversitesi Adresli: Evet

Özet

Epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of multiple malignancies, and its expression also strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of EGFR in epithelial ovarian cancer (EOC) patients.